dc.contributor.author |
Karunanayake, A. |
|
dc.contributor.author |
Devanarayana, N. M. |
|
dc.contributor.author |
De Silva, Asita |
|
dc.contributor.author |
Gunawardena, S. |
|
dc.contributor.author |
Rajindrajith, S. |
|
dc.date.accessioned |
2023-10-23T08:17:33Z |
|
dc.date.available |
2023-10-23T08:17:33Z |
|
dc.date.issued |
2018-05 |
|
dc.identifier.citation |
Karunanayake A, Devanarayana NM, de Silva A, Gunawardena S, Rajindrajith S. Randomized Controlled Clinical Trial on Value of Domperidone in Functional Abdominal Pain in Children. J Pediatr Gastroenterol Nutr. 2018 May;66(5):725-731. doi: 10.1097/MPG.0000000000001819. PMID: 29112086. |
en_US |
dc.identifier.uri |
http://ir.lib.ruh.ac.lk/xmlui/handle/iruor/15229 |
|
dc.description.abstract |
Objectives: The aim of the study was to evaluate the therapeutic effect of domperidone on children with abdominal pain predominant functional gastrointestinal disorders (AP-FGIDs).
Methods: One hundred children (aged 5-12 years) fulfilling Rome III criteria for AP-FGIDs were randomized into 8 weeks of domperidone or placebo treatment. Primary outcomes defined were cure and patient-reported general improvement. Secondary outcomes were reduction in the severity of abdominal pain and increase in gastric motility. Patients were followed up for 6 months.
Results: Eighty-nine (42 in placebo group, 47 in domperidone group) completed the trial at 8 weeks. Seventy-nine completed the 6-month follow-up. When primary outcomes were assessed at 8 weeks, 37 (74%) in the domperidone group and 25 (50%) in the placebo group showed patient-reported general improvement (P = 0.013), whereas no significant difference was observed in cure (22 [44%] vs 14 [28%] P = 0.09). At 6-month follow-up 30 (60%) in the domperidone group and 19 (38%) in the placebo group reported cure (P = 0.028), whereas 44 (88%) in the domperidone group and 33 (66%) in the placebo group showed patient-reported general improvement (P = 0.009). When assessing secondary outcomes at 8 weeks, the domperidone group reported significant reduction in the severity of abdominal pain (54.1% vs 24.7%, P = 0.008) and an increase in the antral motility index (27.5% vs 7.2%, P = 0.029). None of the patients reported intervention-related adverse effects.
Conclusions: Domperidone may be a safe and effective therapeutic modality to achieve a lasting remission of symptoms in children with AP-FGIDs. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
American Academy of Orthopaedic Surgeons |
en_US |
dc.subject |
functional abdominal pain |
en_US |
dc.subject |
functional dyspepsia |
en_US |
dc.subject |
gastric motility |
en_US |
dc.subject |
gastroprokinetics |
en_US |
dc.subject |
irritable bowel syndrome |
en_US |
dc.title |
Randomized Controlled Clinical Trial on Value of Domperidone in Functional Abdominal Pain in Children |
en_US |
dc.type |
Article |
en_US |